Inspra is a medicine containing the active ingredient(s) eplerenone. On this page you will find out more about Inspra, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: eplerenone
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Inspra 25 mg film-coated tablet, 30
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
INSPRA is indicated: To reduce the risk of cardiovascular death in combination with standard therapy in patients who have evidence of heart failure and left ventricular impairment within 3-14 days of an acute myocardial infarction (see CLINICAL TRIALS and DOSAGE AND ADMINISTRATION). To reduce the risk of cardiovascular mortality and morbidity in adult patients with NYHA class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF less than or equal to 30% or LVEF less than or equal to 35% in addition to QRS duration of greater than 130 msec), in addition to standard optimal therapy (see CLINICAL TRIALS).
Table of characteristics
Arc-diamond shape, yellow, film-coated tablet with the following debossing: 'Pfizer' on one side of the tablet, 'NSR' over '25' on the other
Images are the copyright of the Pharmacy Guild of Australia
|Dosage Form||Tablet, film coated|
|Route of administration||Oral|
10, 30, 50, 60: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||No information available|
|Life time||3 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 February 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.